In today's episode, the first in our ongoing “Live Chat” series — informal conversations with members of the medical community, advocates, and patients about what matters most to them and to us, hosts Victoria Goldberg and Dr. Ellen Landsberger are joined by Dr. Sherry Shen, a breast cancer medical oncologist at Memorial Sloan Kettering Cancer Center, for a clear, patient-centered conversation on the evolving role of SERDs (Selective Estrogen Receptor Degraders) in hormone receptor–positive metastatic breast cancer.

Dr. Shen explains the science behind SERDs, the importance of ESR1 mutations, and why oral SERDs are generating excitement. We review recent and ongoing trials—including evERA (giredestrant), SERENA-6 (camizestrant), and updates on FDA‑approved agents such as elacestrant and imlunestrant—while discussing regulatory and insurance hurdles, quality-of-life considerations, side-effect management, and how these drugs are shaping real-world treatment strategies and combination approaches.
Bonus clip: a preview from an upcoming episode with Rebecca Shatsky, MD, where she discusses the evERA trial and shares her enthusiasm for emerging combination strategies, including capivasertib paired with oral SERDs.

Whether you’re a patient, caregiver, or clinician, tune in for practical insights, expert perspectives, and a hopeful look at the future of breast cancer therapy.

Thanks for listening. If you enjoyed the episode, subscribe and leave a review — it really helps. Follow us on social media @livefromstage4 and visit our website at www.livefromstage4.org for show notes and links.

Your support helps us continue to share important stories and advocate for those living with metastatic breast cancer.

Until next time, take care and keep pushing for progress.